The innate immune system is the body’s first line of defense against a range of pathogens, and is exceedingly adept at killing fungal pathogens. Biothera’s Pharmaceutical Group is developing Imprime PGG® to work synergistically with monoclonal antibodies to engage and direct innate immune cells to kill cancer. Clinical research demonstrates the effectiveness of this immunotherapy to significantly improve outcomes in a wide range of cancers. Imprime PGG is currently in multiple Phase 2 clinical trials and a Phase 3 trial for colorectal cancer.
Biothera has a robust pharmaceutical development program that includes advanced clinical trials to treat colorectal cancer, non small cell lung cancer and chronic lymphocytic leukemia. For more information, including trial locations and participation requirements, go to clinical trials.
A "Breakthrough Strategy"
Immunotherapy is being called a “breakthrough strategy” for treating cancer following the presentation of exciting new data at the recent 2013 American Society of Clinical Oncology (ASCO) annual meeting. Read OncLive's “Immunotherapy Hits New Peak: ASCO Data Stir Excitement, Investment” for the full story.
Immunotherapy covers a range of treatments designed to engage the immune system to recognize and kill cancer, often in combination with other drugs. Biothera’s immunotherapeutic drug candidate Imprime PGG has a unique mechanism of action. Its demonstrated ability to direct innate immune cells to kill has produced exciting results in colorectal cancer, non-small cell lung cancer and chronic lymphocytic leukemia.
A study published as the cover story in April 2011 issue of the journal Nature features Biothera’s beta glucans and new discoveries about how these unique immunodulating compounds prime the innate immune system to protect the body. “This research demonstrates that the structure of beta glucans matters,” said William Grossman, M.D., Ph.D., Biothera senior vice president of Research & Development. “Even slight molecular differences in beta glucans affect the signaling pathways used to induce different killing mechanisms. These data expand on our previous research showing that some of our other beta glucan structures bind to CR3, inducing separate and unique mechanisms.” News Release
Biothera's pharmaceutical business has been profiled recently in industry publications targeting investors and potential licensing partners.
This three-minute animation illustrates how Biothera's Imprime PGG® works inside the body to prime innate immune cells to recognize and kill a wide range of pathogens and cancer cells.